Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $49.02 million.

GUIDANCE:

Maravai LifeSciences sees FY2026 revenue of $200-210 million, versus the consensus of $203.3 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.